Product sourcing reference

Cartalax

Cartalax is a short bioregulator peptide from a Russian research series. Evidence is limited, so treat any joint or cartilage claim with caution.

Reference variants

Add Cartalax to an order request

Quantities are individual vials (packs of 10). Orders need 100 vials and/or 20 spray bottles in total, mixed across items. Prices are reference estimates captured 2026-10-16; every request is pending eligibility and availability review. Per-unit figures are rounded to the cent from kit pricing, so a final quote may differ slightly.

20mgVial · confirm physical form

$25.88/vialCloseout estimate Regular $51.75. Subject to confirmation; not a stock promise.

Quantity of Cartalax 20mg in vials vials, packs of 10

Review your order request · Compare the full catalog

Confirm the exact substance

The listing describes the tripeptide Ala-Glu-Asp. Published data come mostly from a small group of laboratories and are not equivalent to controlled clinical trials.

What the review will ask

The reference lists this item at a closeout estimate. That figure is a reference only and does not indicate stock we hold.

State the facility type, destination state and intended transaction. Do not send patient information.
Expect product- and lot-specific documentation to be requested before any material is accepted.
A listed price is a reference estimate. Availability, labeling, shipping and terms are confirmed in writing only after review.

Purchasing questions

Is the closeout price guaranteed?

No. Closeout figures are reference estimates subject to confirmation. Availability is reviewed only after a request is received.

Separate the trade name from the specification

Cartalax's reference price and bioregulator positioning do not establish sequence identity or evidence for a joint-related claim. The closeout label describes pricing, not verified inventory.

Documentation to request

Request a sequence-specific identity document and the source of any proposed benefit claim. Keep the quotation conditional on verified identity and eligibility.

Regulatory context: FDA: compounding, approval and quality standards. Source reviewed 2026-10-16. This source does not verify the identity, testing or availability of our catalog references.

Related guidance: Longevity clinic documentation questions. These references support a review, not a treatment recommendation or supply authorization.

Verify the current regulatory position

Use FDA human drug compounding guidance and applicable state requirements. This reference is not medical or legal advice and does not establish a lawful supply route.

Discuss sourcing requirements